Did electroCore beat or miss consensus estimates last quarter?

What factors drove the changes in electroCore's revenue and profit?

What is electroCore's gross profit margin?

What is the market's earnings forecast for electroCore next quarter?

What were the key takeaways from electroCore’s earnings call?

What does electroCore do and what are its main business segments?

What guidance did electroCore's management provide for the next earnings period?

What were the key takeaways from electroCore's earnings call?

- **Leadership Transition**: CEO Dan Goldberger retiring; CFO Joshua Lev becomes interim president, supported by new COO Michael Fox. 
- **Revenue Growth**: Q4 2025 revenue $9.2M (31% YoY), full year $32M (27% YoY). 
- **VA Dominance**: 200 VA facilities using gammaCore (2% of addressable market); 13,400 patients treated. 
- **DTC Momentum**: Truvaga sales $5.4M (93% YoY), ROAS 2.1x. 
- **New Products**: Quell Relief launch Q2 2026; next-gen app for recurring revenue. 
- **Financials**: Gross margin 87%, net loss $14M (up 19% YoY) due to $7M opex increase.

**【CEO Summary Section】**
- CEO Dan Goldberger announced his retirement effective April 1, 2026, with CFO Joshua Lev assuming interim president duties. 
- New COO Michael Fox (formerly of ProMedTek) will join in April to accelerate VA system adoption and federal healthcare commercialization. 
- 2025 revenue growth driven by VA expansion (200 facilities using gammaCore) and Truvaga DTC sales growth of 97% YoY. 
- 2026 strategy focuses on VA penetration (2% of addressable market), and wellness channel diversification (e.g., Quell Relief launch H1 2026). 

**【CFO Financial Commentary】**
- Q4 2025 revenue: $9.2M (31% YoY), full year $32M (27% YoY). 
- Prescription device revenue up 23% YoY to $26M; Truvaga sales $5.4M (93% YoY). 
- Gross margin improved to 87% (vs. 85% in 2024). 
- Net loss widened to $14M (2024: $11.9M) due to $7M increase in SG&A (sales & marketing +$4.3M). 
- 2026 revenue guidance: ~30% YoY growth, with >80% from VA. 

**【Q&A Highlights】**
- **VA Expansion**: Michael Fox's federal healthcare expertise will drive VA contract optimization and VA/DoD TAC-STIM pipeline acceleration. 
- **DTC Efficiency**: ROAS improved to 2.1x (Q3: 1.8x), targeting 2-2.5x in 2026 via direct-to-consumer focus. 
- **Product Pipeline**: Quell Relief launch Q2 2026; next-gen app development for recurring revenue. 
- **Insurance Reimbursement**: Kaiser contract secured, with plans to leverage success for broader managed care expansion in 2027+.

electroCore, Inc.(ECOR)-20260320-2025 Q4 Earnings call transcript

- **Strategic Acquisitions Pay Off**: Quell Fibromyalgia generated $595K in Q3, exceeding expectations in the VA channel.
- **Revenue Growth Accelerates**: Q3 2025 revenue up 33% YoY to $8.7M, driven by prescription devices and wellness product expansion.
- **AI-Driven Wellness Expansion**: Partnering with StratejAI to develop personalized health apps, targeting $120M wellness market.
- **China Market Opportunity**: Royalty-based commercialization with local licensee, no upfront capital required.
- **Cash Flow Milestones**: Guided for cash positive by Q2 2026 with $12M quarterly revenue.

**【Chairman's Strategic Vision】**
- Acquired NeuroMetrix's Quell portfolio for fibromyalgia treatment, entering the $1.3B global pain management market with a CAGR of 7%.
- Expanded VA sales team and secured a 5-year contract, targeting 550K fibromyalgia patients in the VA system.
- Launched wellness division with Truvaga, aiming for $80M-$120M global wellness opportunity, and partnered with StratejAI for AI-driven health apps.
- Established China partnership for royalty-based commercialization, leveraging local regulatory expertise without capital investment.

**【CEO's Quarterly Performance Review】**
- Q3 2025 revenue reached $8.7M (33% YoY growth), driven by 19% YoY prescription device sales and 54% sequential wellness product growth.
- Quell Fibromyalgia generated $595K in Q3 revenue, exceeding internal expectations; Truvaga sales returned to growth, excluding a $500K clinical trial order.
- VA penetration at 2% of addressable headache market, with 195 facilities using gammaCore (up from 166 YoY).
- Guidance: Full-year 2025 revenue $31.5M-$32.5M; cash positive by Q2 2026 with $12M quarterly revenue.

**【CFO's Financial Commentary】**
- Q3 2025 net loss $3.4M (-$0.40 EPS), driven by $384K CVR liability and $150K interest expense.
- Adjusted EBITDA loss $2M, improving from $2.1M YoY.
- Cash balance $13.2M as of Sep 30, 2025; forecast $10.5M at year-end.
- Operating expenses up 23% YoY to $10.4M, reflecting investments in sales, marketing, and R&D.

**【Q&A Highlights】**
- Quell Fibromyalgia adoption in VA outperformed expectations, with rheumatology and pain specialists prioritizing safety and efficacy.
- Truvaga's next-gen app focuses on wellness data personalization, with potential recurring revenue streams.
- China licensee plans CFDA approval for prescription devices, with royalties to begin post-commercialization.
- TAC-STIM military sales lumpy but expected $400K annualized in 2026.
- PTSD and mild TBI clinical trials planned for 2026, targeting FDA label expansion.

electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript

- **Revenue Milestone**: Q2 2025 revenue of $7.4 million marks 20% YoY growth, driven by VA expansion and Truvaga's 74% YoY sales surge.
- **Strategic Debt Financing**: $12 million Avenue Capital facility to accelerate growth in health/wellness and prescription channels.
- **Gross Margin Strength**: 87% gross margin sustained, supporting 55%+ contribution margin for future scale.
- **New Product Momentum**: Quell Fibromyalgia production line operational, targeting late 2025 revenue contribution.
- **Cash Flow Management**: Pro forma cash balance of $10.5 million by year-end, with $11.5-$12 million quarterly revenue target for 2026 cash positivity.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q2 2025 revenue reached $7.4 million, up 20% YoY and 10% sequentially, driven by VA channel growth and Truvaga sales.
- **VA Channel Expansion**: VA revenue grew 12% sequentially to $5.3 million, with 188 VA facilities now using gammaCore. Addressable market includes 550,000 fibromyalgia patients in the VA system.
- **Truvaga Performance**: Direct-to-consumer brand Truvaga posted $1 million in Q2 sales (74% YoY growth), with a 2.0 return on advertising spend. Truvaga Plus accounts for 80% of revenue.
- **Strategic Investments**: $12 million debt facility with Avenue Capital to fund growth in Truvaga and prescription products. Operating expenses will increase to $11.5-$12 million quarterly to achieve cash positivity by 2026.
- **New Product Launches**: Quell Fibromyalgia production line operational, with samples distributed to sales teams for late 2025 revenue contribution.

**【CFO Financial Commentary】**
- **Financials**: Q2 2025 GAAP net loss of $3.7 million (-15% YoY), with gross margin at 87%. Operating expenses rose 25% YoY to $9.9 million due to marketing and R&D investments.
- **Cash Position**: $7.4 million cash as of June 30, 2025, with $7.2 million from Avenue Capital. Pro forma cash balance expected to reach $10.5 million by year-end.
- **Guidance**: Full-year 2025 revenue outlook maintained at $30 million, with net cash usage of $3.9-$4.4 million for the next two quarters.

**【Q&A Key Highlights】**
- **Truvaga SKU Performance**: Truvaga Plus (mobile-enabled) accounts for 80% of revenue, while Truvaga 350 lags due to limited features.
- **Legal Actions**: Patent infringement lawsuits filed in U.S. District Court; legal expenses incurred in Q1/Q2 2025.
- **Amazon Sales**: Integration challenges with Amazon fulfillment; no material contribution yet.
- **Marketing Spend**: SG&A scales with revenue (30% variable component), with Q2 2025 spend up $300,000 sequentially.
- **Profitability Timeline**: Target $11.5 million quarterly revenue to achieve cash positivity, expected by late 2026.
- **Apple Health Integration**: Truvaga app compatibility with Apple Health API to expand biohacker use cases.


electroCore, Inc. (ECOR) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 up 23% to $6.7M, driven by 22% VA gammaCore growth and 187% Truvaga DTC expansion.
- **Quell Acquisition**: Q1 2025 Quell revenue ~$170K, targeting >60% gross margin post-manufacturing ramp in Q2.
- **Cash Efficiency**: $4.2M Q1 cash use, modeling $2M Q2 spend, with path to cash neutrality at $9M quarterly revenue.
- **Truvaga Momentum**: 10% return rate, 2.26 ROAS, Amazon sales >200 units since launch, Apple Health integration.
- **New Products**: Sparrow Ascent in VA opioid withdrawal pilots, Quell 2.0 for lower extremity pain launching in 2025.

**【CEO Opening Remarks】**
- Q1 2025 revenue: $6.7 million (23% YoY growth), driven by prescription gammaCore VA sales ($4.7M, +22%) and Truvaga DTC growth (187%).
- Acquired Quell fibromyalgia product line from NeuroMetrix, with Q1 2025 Quell revenue ~$170K (preliminary).
- Target 2025 full-year revenue: $30 million, with cash usage modeled at $3.8-4.3M.
- VA channel momentum: 175 VA facilities now using gammaCore (vs. 151 in Q1 2024), with Q2 2025 monthly sales ~$1.7M.
- Truvaga DTC: 14,000+ units sold, 500K+ app sessions, 10% return rate, ROAS 2.26 in Q1.
- Launching Quell 2.0 for lower extremity pain and Sparrow Ascent for opioid withdrawal in VA pilots.

**【CFO Financial Highlights】**
- Gross margin: 85% (flat vs. 84% in Q1 2024), with $5.7M gross profit.
- Operating expenses: $9.5M (13% YoY increase), driven by R&D (+64%) and G&A (+11%).
- Net loss: $3.9M (vs. $3.5M in Q1 2024), with adjusted EBITDA loss of $3.1M.
- Cash position: $8M as of March 31, 2025 (down from $12.2M at year-end 2024) due to seasonal disbursements and acquisition costs.

**【Q&A Key Takeaways】**
1. **Quell Margins**: CFO expects >60% gross margin post-manufacturing ramp (vs. NeuroMetrix's 55% in 2024), with Q2 2025 revenue similar to Q1 (~$170K).
2. **Tariff Risk**: Minimal exposure; <5% of direct materials sourced from China/Southeast Asia.
3. **Cash Outlook**: $4.2M used in Q1, ~$2M expected in Q2, with cash neutral at $9M quarterly revenue (~34% above Q1 level).
4. **TAC-STIM**: Lumpy sales (~$90K in Q1), but RFPs for >$1M in potential contracts.
5. **Truvaga Expansion**: Amazon sales >200 units since launch, Apple Health integration driving awareness.
6. **NeuroMetrix Integration**: Manufacturing restart in Q2, targeting 2026 for material Quell revenue contribution.
7. **R&D Focus**: PTSD indication pending FDA feedback, TBI data publication in 2025.
8. **G&A Management**: 2025 G&A expenses expected to match 2024 levels (~$8M annually).

electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript

- **Revenue Surge**: 2024 revenue up 57% to $25.2M, driven by VA ($17.8M, +85%) and Truvaga ($2.8M, +174%). Q4 revenue grew 36% YoY to $7M.
- **Margin Strength**: Gross margin improved to 85%, with plans to maintain mid-80s range despite trade policy challenges.
- **Strategic Acquisitions**: NeuroMetrix (Quell fibromyalgia) and Spark Biomedical (Sparrow) expand addressable markets in chronic pain and opioid withdrawal.
- **Military Expansion**: TAC-STIM human performance device sees interest from special ops units, though DoD adoption may take 3-4 years.
- **Cash Position**: $12.2M cash on hand, with disciplined expense management and no immediate capital needs.


**【CEO Opening Remarks】**
- **Revenue Growth**: Full-year 2024 revenue reached $25.2 million, up 57% YoY, driven by VA channel sales ($17.8M, +85%) and Truvaga wellness product sales ($2.8M, +174%). Q4 revenue was $7M, a 36% YoY increase.
- **Gross Margin**: Full-year gross margin improved to 85% (vs. 83% in 2023), with plans to maintain mid-80s margins despite trade policy headwinds.
- **Key Acquisitions**: Announced acquisition of NeuroMetrix (Quell fibromyalgia device) and distribution deal with Spark Biomedical (Sparrow opioid withdrawal therapy), targeting VA and military markets.
- **Pipeline Expansion**: Exploring new indications for gammaCore (e.g., PTSD) and expanding Truvaga into international markets (Canada, UK) in 2025.

**【CFO Financial Highlights】**
- **Net Sales**: $25.2M (2024) vs. $16M (2023), driven by VA ($17.8M, +85%) and Truvaga ($2.8M, +174%).
- **Gross Profit**: $21.4M (2024) vs. $13.2M (2023), with 85% margin maintained.
- **Operating Expenses**: $33.6M (2024) vs. $32.5M (2023), driven by sales & marketing growth (+$3.1M).
- **Net Loss**: $11.9M (2024) vs. $18.8M (2023), narrowing by 37%.
- **Cash Position**: $12.2M at year-end, up from $10.6M, with $7M net cash used in operations (vs. $14.7M in 2023).

**【Q&A Key Takeaways】**
1. **NeuroMetrix Integration**: Post-acquisition, Quell fibromyalgia will be added to VA FSS contract and sold through existing sales channels. 2025 focus on VA adoption, with OTC launch for lower extremity pain in 2026.
2. **Joerns/Kaiser Channel**: Slow traction in commercial insurance channel, but 30+ prescribers now active in Kaiser system. Expect gradual growth as training expands.
3. **Military Sales**: TAC-STIM for human performance shows interest from Air Force & Army Special Forces, but DoD acquisition timeline uncertain (3-4 years for contract of record).
4. **Truvaga Growth**: Q4 sales $1.2M (+271% YoY), with Amazon launch in Feb 2025. Holiday season boost normalized, but ROAS remains strong at $2.99/Media in Q4.
5. **VA Contract Risk**: VA personnel reductions may cause supply chain delays, but clinical adoption of gammaCore remains strong due to cost-effectiveness vs. pharmaceuticals.


Actual								-4.05	-1.95	-1.5	-2.1	-1.65	-0.9	-0.9	-1.05	-1.2	-1.2	-1.2	-1.22	-1.24	-1.03	-0.68	-0.61	-0.53	-0.38	-0.31	-0.37	-0.47	-0.44	-0.4	-0.34
Forecast								-3.375	-2.95	-2.05	-1.5798	-1.6875	-1.68	-1.2	-1.025	-0.99	-1.1	-1.05	-1.116	-0.996	-0.9633	-0.6967	-0.592	-0.588	-0.43	-0.326	-0.3	-0.4825	-0.325	-0.4	-0.402
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-20.00%	+33.90%	+26.83%	-32.93%	+2.22%	+46.43%	+25.00%	-2.44%	-21.21%	-9.09%	-14.29%	-9.32%	-24.50%	-6.92%	+2.40%	-3.04%	+9.86%	+11.63%	+4.91%	-23.33%	+2.59%	-35.38%	0.00%	+15.42%

ECOR

ECOR fundamentals

ECOR Q4 2025 Earnings

Earnings Call

You can ask Aime

ECOR

ECOR fundamentals

ECOR Q4 2025 Earnings

Earnings Call

ECOR Earnings Call Summary for Q4/20254:30 PM on Mar 19, 2026

ECOR Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

ECOR Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

ECOR Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

ECOR Earnings Call Summary for Q4/20245:30 PM on Mar 12, 2025

You can ask Aime